Skip to search formSkip to main contentSkip to account menu

tasquinimod

Known as: TASQ 
A quinoline-3-carboxamide linomide analogue with antiangiogenic and potential antineoplastic activities. Tasquinimod has been shown to decrease blood… 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

ABR-215050
NCIt Antineoplastic Agent Terminology

Broader (1)

Quinolines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b+ Ly6Chi cells to tumor tissue reduces tumor growth
Previous work has demonstrated immunomodulatory, anti-tumor, anti-metastatic and anti-angiogenic effects of the small molecule… 
Review
2016
Review
2016
A Phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castration-resistant prostate cancer (mCRPC), secondary endpoints.
239 Background: TASQ is an oral agent with immunomodulatory, anti-angiogenic and anti-metastatic properties that targets the… 
Review
2014
Review
2014
Anti-angiogenesis in prostate cancer: knocked down but not out
Angiogenesis is a very complex physiological process, which involves multiple pathways that are dependent on the homeostatic… 
2014
2014
Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment
Tasquinimod, an orally active quinoline-3-carboxamide, binds with high affinity to HDAC4 and S100A9 in cancer and infiltrating… 
Review
2014
Review
2014
Pharmacotherapeutic Management of Metastatic, Castration-Resistant Prostate Cancer in the Elderly: Focus on Non-Chemotherapy Agents
In the past 4 years, five new agents have been approved for metastatic, castration-resistant prostate cancer. Four of them are… 
2013
2013
Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer
Androgen deprivation therapy (ADT) with medical or surgical castration is the mainstay of therapy in men with metastatic prostate… 
Review
2013
Review
2013
Tasquinimod: A Novel Angiogenesis Inhibitor–Development in Prostate Cancer
Castration resistant prostate cancer (CRPC) treatment has been revolutionized over the past few years by the approval of novel… 
2011
2011
Phase II study of tasquinimod in chemotherapy-naive patients with metastatic castrate-resistant prostate cancer (CRPC): Safety and efficacy analysis including subgroups.
126 Background: Tasquinimod (TASQ) is an oral quinoline-3-carboxamide derivative that binds to S100A9 and displays anti… 
Highly Cited
2009
Highly Cited
2009
Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer
Background:Tasquinimod is a quinoline-3-carboxamide derivative with anti-angiogenic activity. Two open-label phase I clinical… 
2004
2004
Äspö HRL : Experiences of blasting the TASQ tunnel
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)